Centrum Medyczne ENEL-MEDWAR:ENE 78 EBITDA Margin % is 12.51% as of Mar. 2026, which is 7% below its 10-year median of 13.46. GuruFocus rates WAR:ENE with a GF Score™ of 78/100 and a GF Value™ of zł24.91 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Centrum Medyczne ENEL-MED ranks better than 56.74% on this metric.
Centrum Medyczne ENEL-MED (WAR:ENE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Centrum Medyczne ENEL-MED EBITDA Margin % Related Terms
Centrum Medyczne ENEL-MED EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:ENE vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Centrum Medyczne ENEL-MED's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Centrum Medyczne ENEL-MED EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Centrum Medyczne ENEL-MED's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Centrum Medyczne ENEL-MED's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Centrum Medyczne ENEL-MED (WAR:ENE) has a EBITDA Margin % of 12.51% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Centrum Medyczne ENEL-MED and its competitors. This is near median its historical median of 13.46. Over the past decade, Centrum Medyczne ENEL-MED's EBITDA Margin % has ranged from 5.51 to 15.09. According to the industry distribution chart, Centrum Medyczne ENEL-MED ranks #289 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 43.3%.
Is Centrum Medyczne ENEL-MED's EBITDA Margin % too high?
Centrum Medyczne ENEL-MED's current EBITDA Margin % of 12.51% is near median its 10-year median of 13.46. Over the past 10 years, this metric has ranged from a low of 5.51 to a high of 15.09. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Centrum Medyczne ENEL-MED's value of 12.51% is 22.5% above this industry median. Based on the distribution chart, Centrum Medyczne ENEL-MED ranks #289 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Centrum Medyczne ENEL-MED has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Centrum Medyczne ENEL-MED's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Centrum Medyczne ENEL-MED ranks #289 out of 668 companies for EBITDA Margin %. This puts Centrum Medyczne ENEL-MED in the upper half of its industry. The industry median EBITDA Margin % is 10.21. Centrum Medyczne ENEL-MED's value of 12.51% is 22.5% above this benchmark. Historically, Centrum Medyczne ENEL-MED's own EBITDA Margin % has ranged from 5.51 to 15.09 over the past decade. While the company's 10-year median is 13.46 vs. the industry median of 10.21, Centrum Medyczne ENEL-MED has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Centrum Medyczne ENEL-MED's current EBITDA Margin % of 12.51% is 22.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Centrum Medyczne ENEL-MED and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Centrum Medyczne ENEL-MED's current EBITDA Margin % is 12.51%, which is near median its own 10-year median of 13.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centrum Medyczne ENEL-MED stock overvalued right now?
Based on GuruFocus' analysis, Centrum Medyczne ENEL-MED (WAR:ENE) is currently considered Modestly Undervalued. The stock's GF Value™ is zł24.91, compared to a current price of zł19.20 — trading 22.9% below its estimated fair value. The current EBITDA Margin % is 12.51%, which is near median its 10-year median of 13.46 and 22.5% above the Healthcare Providers & Services industry median of 10.21. Centrum Medyczne ENEL-MED's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Centrum Medyczne ENEL-MED (WAR:ENE), the current EBITDA Margin % is 12.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Centrum Medyczne ENEL-MED (WAR:ENE) Overvalued in 2026?
Based on GuruFocus' analysis, Centrum Medyczne ENEL-MED stock appears to be undervalued.
The current stock price of zł19.20 is trading 22.9% below its estimated GF Value™ of zł24.91.
GuruFocus considers Centrum Medyczne ENEL-MED to be Modestly Undervalued.
Key valuation signals for WAR:ENE:
EBITDA Margin %: 12.51% (near median its 10-year median of 13.46)
GF Value™: zł24.91 vs. price of zł19.20 (22.9% below fair value)
Industry Position: 22.5% above the Healthcare Providers & Services median (#289 of 668)
No single metric tells the full story. See the WAR:ENE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Centrum Medyczne ENEL-MED SA is engaged in providing medical services throughout Poland region. The company is involved in providing various services that are dentistry, picture diagnosis, clinics, subscription for companies, and medical insurance. It also provides hospitals, aesthetic medicines, and sports medicine. The company's treatment cycle consists of consultation, diagnosis, hospitalization, surgery, and rehabilitation.
78GF Score
Get the complete analysis for WAR:ENE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:ENE has been successfully added to your 
